P02.4 Navigated brain stimulation (NBS) shows increased motor thresholds in intractable focal epilepsy due to cortical dysplasia

2006 ◽  
Vol 117 ◽  
pp. 126
Author(s):  
E. Mervaala ◽  
M. Könönen ◽  
L. Eskola ◽  
S. Teitti ◽  
S. Määttä ◽  
...  
2009 ◽  
Vol 40 (01) ◽  
Author(s):  
S Schmidt ◽  
E Holst ◽  
K Irlbacher ◽  
M Merschhemke ◽  
SA Brandt

2020 ◽  
Vol 5 ◽  
pp. 142-146
Author(s):  
Miguel Muñoz-Ruiz ◽  
Janne Nordberg ◽  
Jaana Lähdetie ◽  
Satu K. Jääskeläinen

2006 ◽  
Vol 117 ◽  
pp. 1-2
Author(s):  
S. Teitti ◽  
S. Määttä ◽  
L. Eskola ◽  
M. Könönen ◽  
R. Vanninen ◽  
...  

2014 ◽  
Vol 156 (6) ◽  
pp. 1125-1133 ◽  
Author(s):  
Thomas Picht ◽  
Sarah Schilt ◽  
Dietmar Frey ◽  
Peter Vajkoczy ◽  
Markus Kufeld

2020 ◽  
Vol 81 (04) ◽  
pp. 368-371
Author(s):  
Bogdan Pintea ◽  
Rainer Surges ◽  
Jan Boström

Abstract Objective Headache disorders are frequently associated with epilepsy. Some neuromodulation techniques for refractory epilepsy have been reported to positively influence the associated chronic headache. However, the exact mechanism of action of vagus nerve stimulation (VNS) and anterior thalamic nuclei-deep brain stimulation (ANT-DBS) on pain perception is unclear. Method We report a structured assessment of pain perception in a patient who experienced headache relief after ANT-DBS for refractory focal epilepsy and compare it with pain perception of epilepsy patients with chronic headache who were treated with and without VNS. Results The pain-associated symptoms in the ANT-DBS case were on the Pain Anxiety Symptoms Scale (PASS-40) subscore “physiological anxiety” closer to the control collective, whereas in patients with VNS, this was more likely for the PASS-40 subscores “cognitive anxiety” or “escape and avoidance.” Conclusion ANT-DBS and VNS may influence epilepsy-associated chronic headache in different ways.


2011 ◽  
Vol 114 (4) ◽  
pp. 1195-1202 ◽  
Author(s):  
Jorge A. González-Martínez ◽  
Zhong Ying ◽  
Richard Prayson ◽  
William Bingaman ◽  
Imad Najm

Object Changes in the expression of glutamate transporters (GLTs) may play a role in the expression of epileptogenicity. Previous studies have shown an increased number of neuronal GLTs in human dysplastic neurons. The expression of glial and neuronal GLTs and glutamine synthetase (GS) in balloon cells (BCs) and BC-containing cortical dysplasia has not been studied. Methods The authors analyzed neocortical samples that were resected in 5 patients who had cortical dysplasia–induced medically intractable focal epilepsy and who underwent extraoperative prolonged electrocorticographic (ECoG) recordings. The expressions of glial (GLT1/EAAT2) and neuronal (EAAT3, EAAC1) GLTs and GS proteins were immunohistochemically studied in all 5 resected samples. The authors also assessed in situ colocalization of GLTs and GS with neuronal and glial markers. Results Balloon cell–containing cortical dysplasia lesions did not exhibit ictal patterns on prolonged extraoperative ECoG recordings. There was a differential expression of glial and neuronal GLTs in BCs and dysplastic neurons: the majority of BCs highly expressed glial but not neuronal GLTs. Dysplastic neurons showed increased immunohistochemical staining with neuronal EAAT3 but not with EAAT2/GLT1. Moreover, only glial fibrillary acidic protein–positive BCs also expressed GS. Conclusions There is a differential GLT expression in dysplastic and balloon cells. The presence of glial GLTs and GS in balloon cell cortical dysplasia suggests a possible antiepileptic role for BCs and is consistent with the reported increased epileptogenicity in GLT1-deficient animals.


Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Richard L Harvey ◽  
Charles Liu ◽  
Dylan Edwards ◽  
Kari Dunning ◽  
Felipe Fregni ◽  
...  

Introduction: Upper limb function following stroke is limited, with only 50% regaining some function and less than 20% regaining normal function. Repetitive TMS has promise as an adjunct to upper limb therapy after stroke. We aimed to determine if navigated brain stimulation (NBS) with a low-frequency (1 Hz) protocol to non-injured hemisphere combined with upper limb rehabilitation would improve arm motor function better than rehabilitation alone. Method: We enrolled 199 patients with hemiplegia from ischemic or hemorrhagic stroke within 3-12 m post ictus. Randomization was in a 2:1 ratio to NBS with 18 sessions of rehabilitation over 6 weeks, or to sham NBS with therapy. The primary end-point was rate of achieving a 5-point improvement on the upper limb Fugl-Myer (ULFM) score at 6 m post-treatment and safety. Secondary outcomes included post-treatment, 1 m, 3 m and 6 m change on ULFM, action research arm test (ARAT), and EQ-5D-3L health questionnaire. Results: Of 199 subjects enrolled, 167 completed treatment and follow-up due to early stoppage of data collection after interim futility analysis. All subjects improved significantly on each outcome measure at each point of follow up, including 6 m post-treatment ULFM: treatment (8.1±7.4, p<0.001) and sham (8.5±8.7, p<0.001). In the ITT analysis, there was no difference on achievement of 5 points on ULFM at 6 m post-treatment: 67% treatment vs. 65% sham (chi-sq 1.105, p=0.76). Repeated measures ANCOVA group*time interaction showed no significant difference between groups for ULFM (p=0.87), ARAT (p=0.80) and the EQ 5D (p=0.96). There were no study or device related serious adverse events and no difference in SAE’s between groups. Conclusion: NBS can be safely used in the clinical setting. Clinically important gains were observed in both study arms suggesting no additional effect of 1 Hz NBS in stroke subjects within 3-12 m post ictus. The lack of NBS effects may be explained by the large effect size (ceiling effect) or potentially that the sham coil unintentionally induced cortical currents. Further analysis of the sham method and also secondary subgroup analyses will provide further insights and generate novel hypothesis to be confirmed in future NBS trials.


Sign in / Sign up

Export Citation Format

Share Document